Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AXNX vs ATRC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATRC Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–0 Matrix Metrics)

ATRC Overall Winner 6-Pillar Tally: AXNX 0 – 5 ATRC (1 Tie) Matrix Metrics: AXNX 0 – 9 ATRC

As of Nov 20, 2026, AtriCure, Inc. (ATRC) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas ATRC carries 53.7/100 (HOLD) at $55.39 (122.1x Forward P/E, 2.9% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AXNX vs ATRC
AXNX US Equity
AXNX
Institutional Equity
$0.83
-8.28% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
52.1 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
ATRC NASDAQ Head-to-Head Winner
AtriCure, Inc.
Surgical & Medical Instruments & Apparatus
$55.39
+2.37% 1D
Market Cap $2.8B
TTM Revenue $590M
Forward P/E 122.1x
Beta / 30D Vol 0.47β · 49% Vol
Unified Composite Score
53.7 / 100 HOLD
Tech 42.0 Fund 47.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 44.8 · SMA20: $58.65 · SMA50: $57.67

6-Pillar Scorecard Institutional Category Breakdown (AXNX 0 – 5 ATRC)

Columns: Metric · AXNX · ATRC
1. Valuation Multiples ATRC
Forward P/E N/M 122.1x
Trailing P/E N/M N/M
PEG Ratio N/M 10.00x
EV / Revenue N/M 4.7x
2. Growth & Scale ATRC
Revenue Growth (YoY) N/A +15.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $590M
Market Cap N/A $2.8B
3. Profitability & Quality ATRC
Gross Margin N/A 76.7%
Operating Margin N/A 2.9%
Net Profit Margin N/A 2.5%
Return on Equity (ROE) N/A 2.9%
4. Balance Sheet & Cash Flow ATRC
Cash Generation (TTM) N/A $38M EBITDA
Cash Flow Margin N/A 6.5% EBITDA Mgn
Net Cash / Leverage N/A ROE $10.47 Book/Sh · 2.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 44.5% (74th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ATRC
OpEx & R&D Intensity N/A 73.8% of Rev ($435M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AXNX (0) vs ATRC (9)
Institutional Metric AXNX ATRC Criterion Row Edge
Market Capitalization
Scale
N/A $2.8B Larger Scale ATRC
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M 122.1x Lower Multiple ATRC
Revenue Growth (YoY)
Growth
N/A +15.0% Higher Growth ATRC
Operating Margin (TTM)
Profitability
N/A 2.9% Higher Margin ATRC
Net Profit Margin
Profitability
N/A 2.5% Higher Margin ATRC
Return on Equity (ROE)
Capital Efficiency
N/A 2.9% Higher ROE ATRC
52-Week Range Position
Momentum
50% ($0–$1) 74% ($25–$66) Stronger Trend ATRC
Beta / 30D Volatility
Risk Regime
N/A 0.47β · 49% Vol Lower Realized Risk ATRC
Unified Institutional Score
Composite Signal
52.1 / 100 (HOLD) 53.7 / 100 (HOLD) Higher Composite ATRC
Trailing 12M Revenue (USD)
Operating Scale
N/A $590M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 76.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 10.00x PEG · 4.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $38M EBITDA ($10.47 Book/Sh · 2.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATRC +19.95 pp
AXNX: -26.54% · ATRC: -6.59%
3M Horizon AXNX +19.52 pp
AXNX: +16.92% · ATRC: -2.6%
6M Horizon AXNX +19.52 pp
AXNX: +16.92% · ATRC: -2.6%
1Y Horizon AXNX +19.52 pp
AXNX: +16.92% · ATRC: -2.6%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AXNX vs ATRC. Trailing 12-month operating profitability (AXNX N/A vs ATRC 2.9%) and valuation multiples (AXNX N/M vs ATRC 122.1x Forward P/E) are benchmarked directly in Pillar 4 below.

AXNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ATRC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$590M
Gross Margin76.7%
Op. Margin2.9%
ROE / Fwd P/E2.9% · 122.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AXNX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AXNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ATRC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 44.5%
IV Percentile 74th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ATRC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AXNX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ATRC Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $2.8B market capitalization and 2.9% operating margin.
OpEx & R&D Reinvestment 73.8% of Rev ($435M)
90D Engineering Disclosures 0 Published

Investor FAQ AXNX vs ATRC Key Questions & Quantitative Answers

As of Nov 20, 2026, AtriCure, Inc. (ATRC) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas ATRC carries 53.7/100 (HOLD) at $55.39 (122.1x Forward P/E, 2.9% operating margin). Technically, AXNX sits in a Neutral phase (RSI N/A, UNCLASSIFIED options structure) and ATRC sits in a Neutral phase (RSI 44.8, UNCLASSIFIED options structure).

ATRC leads the Growth & Scale pillar: AXNX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ATRC at +15.0% YoY revenue growth and +0.0% YoY earnings growth on $590M TTM revenue (76.7% gross margin, 2.9% operating margin). On trailing 12-month operating scale, AXNX generates N/A in USD-normalized revenue versus $590M for ATRC. In operating R&D and SG&A reinvestment, AXNX deploys N/A (0 90-day corporate R&D disclosures) versus 73.8% of Rev ($435M) (0 disclosures) for ATRC.

ATRC screens cheaper on headline valuation multiples. AXNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ATRC trades at 122.1x Forward P/E, N/M Trailing P/E, 10.00x PEG, and 4.7x EV/Revenue (6.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AXNX (N/A ROE) versus ATRC (2.9% ROE) capital efficiency.

In options market volatility and institutional positioning, AXNX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, ATRC carries 44.5% implied volatility (74th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.47β · 49% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.